Biotechnology company developing novel oncolytic virus-based immunotherapies for the treatment of cancer.
Turnstone Biologics Corp., a clinical-stage biotechnology company, is dedicated to advancing therapies aimed at treating and curing patients afflicted with solid tumors. The company's primary focus lies in developing innovative medicines that harness the power of oncolytic viral immunotherapies.
At the forefront of Turnstone Biologics' pipeline is TIDAL-01, its lead product currently undergoing Phase 1 clinical trials. This therapeutic candidate shows promising potential in the treatment of various cancers, including breast cancer, colorectal cancer, head and neck cancer, and uveal melanoma. Additionally, the company is involved in investigator-sponsored trials targeting colorectal cancer, head and neck cancer, and both cutaneous and non-cutaneous melanomas.
Further expanding its therapeutic portfolio, Turnstone Biologics is actively developing TIDAL-02, an innovative treatment in preclinical stages. This next-generation therapy aims to address the challenges posed by solid tumors, leveraging cutting-edge research and development methodologies.
Established in 2014 and headquartered in La Jolla, California, Turnstone Biologics is strategically positioned within a vibrant biotechnology ecosystem. Since its inception, the company has been committed to pioneering advancements in oncolytic viral immunotherapy, driven by a dedication to improving patient outcomes and transforming the landscape of cancer treatment.